Latest ImaginAb Inc. Stories
-Enhances Capabilities for the Precision Medicine in Immuno-oncology and Autoimmune Disease Areas- LOS ANGELES and LEIPZIG, Germany, Sept. 17, 2014 /PRNewswire/ -- ImaginAb, Inc.
LOS ANGELES, SINGAPORE, and TOKYO, July 28, 2014 /PRNewswire/ -- ImaginAb, Inc.
NEW YORK and LOS ANGELES, June 10, 2014 /PRNewswire/ -- NCM USA announced today it has signed a long-term clinical zirconium isotope ((89)Zr) supply and cGMP biologics labeling agreement with
IBA to Manufacture and Supply 89Zr-Df-IAB2M for Multi-Center Studies in the US LOS ANGELES and DULLES, Va., June 9, 2014 /PRNewswire/ -- ImaginAb, Inc.
Initial clinical experience with 89Zr-labeled anti-PSMA minibody presented LOS ANGELES, June 6, 2014 /PRNewswire/ -- ImaginAb, Inc., in collaboration with Memorial Sloan-Kettering
ImaginAb Expands Portfolio for Immunotherapeutic Drug Development LOS ANGELES, June 3, 2014 /PRNewswire/ -- ImaginAb, Inc.
LOS ANGELES and SINGAPORE, May 8, 2014 /PRNewswire/ -- ImaginAb, Inc., a clinical stage biotechnology company that engineers antibodies into smaller protein formats optimized for in vivo
Major new precision medicine initiative takes root in Singapore SINGAPORE and LOS ANGELES, Feb. 10, 2014 /PRNewswire/ -- ImaginAb, Inc.
- A transitional zone between two communities containing the characteristic species of each.